Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoMEX:4519N 97 Shareholder Yield % is 1.88% as of Mar. 2026, which is 39% above its 10-year median of 1.35. GuruFocus rates MEX:4519N with a GF Score™ of 97/100 and a GF Value™ of MXN873.09. The stock has 1 warning sign investors should review. Among 972 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 64.61% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Chugai Pharmaceutical Co's Shareholder Yield % was 1.88%.
Chugai Pharmaceutical Co (MEX:4519N) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Chugai Pharmaceutical Co Shareholder Yield % Related Terms
Chugai Pharmaceutical Co Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Shareholder Yield % Chart
MEX:4519N vs LLY, JNJ, ABBV: Shareholder Yield % Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Chugai Pharmaceutical Co (MEX:4519N) has a Shareholder Yield % of 1.88% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Chugai Pharmaceutical Co and its competitors. This is 39% above median its historical median of 1.35. Over the past decade, Chugai Pharmaceutical Co's Shareholder Yield % has ranged from 0.70 to 2.41. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #344 out of 972 companies in the Drug Manufacturers industry, placing it in the top 35.4%.
Is Chugai Pharmaceutical Co's Shareholder Yield % too high?
Chugai Pharmaceutical Co's current Shareholder Yield % of 1.88% is 39% above median its 10-year median of 1.35. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 2.41. The Drug Manufacturers industry median Shareholder Yield % is 0.29. Chugai Pharmaceutical Co's value of 1.88% is 548.3% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #344 out of 972 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Shareholder Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #344 out of 972 companies for Shareholder Yield %. This puts Chugai Pharmaceutical Co in the upper half of its industry. The industry median Shareholder Yield % is 0.29. Chugai Pharmaceutical Co's value of 1.88% is 548.3% above this benchmark. Historically, Chugai Pharmaceutical Co's own Shareholder Yield % has ranged from 0.70 to 2.41 over the past decade. While the company's 10-year median is 1.35 vs. the industry median of 0.29, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.29, based on 972 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Shareholder Yield % of 1.88% is 548.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Shareholder Yield % is 1.88%, which is 39% above median its own 10-year median of 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Chugai Pharmaceutical Co (MEX:4519N) has a current Shareholder Yield % of 1.88%. The stock's GF Value™ is MXN873.09, compared to a current price of MXN825.61 — trading 5.4% below its estimated fair value. The current Shareholder Yield % is 1.88%, which is 39% above median its 10-year median of 1.35 and 548.3% above the Drug Manufacturers industry median of 0.29. Chugai Pharmaceutical Co's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Chugai Pharmaceutical Co (MEX:4519N), the current Shareholder Yield % is 1.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of MXN825.61 is trading 5.4% below its estimated GF Value™ of MXN873.09.
Key valuation signals for MEX:4519N:
Shareholder Yield %: 1.88% (39% above median its 10-year median of 1.35)
GF Value™: MXN873.09 vs. price of MXN825.61 (5.4% below fair value)
Industry Position: 548.3% above the Drug Manufacturers median (#344 of 972)
No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score
Get the complete analysis for MEX:4519N
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4519N has been successfully added to your 
